DB Wealth Management Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

DB Wealth Management Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$3.66K	Buy	+41	New	+$3.04K	﹤0.01%	328

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

DB Wealth Management Group's XBI Position: Q4 2023 in Review

DB Wealth Management Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2023: 41 shares worth $3.66K. The stake represents ﹤0.01% of the portfolio and ranks #328 among its holdings.

745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

DB Wealth Management Group held 41 shares of State Street SPDR S&P Biotech ETF worth $3.66K as of Q4 2023.
State Street SPDR S&P Biotech ETF was a new DB Wealth Management Group position in Q4 2023.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of DB Wealth Management Group's portfolio in Q4 2023, its #328 holding.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on DB Wealth Management Group's 13F filing for Q4 2023, filed 9 Jan 2024.